RBGPF Stock Recent News

City analysts were mostly in reaction mode on Thursday as the square-mile's CFA'd scribes continued to digest what has been a busy week of trading updates and results in London's mid-cap segment. Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) was tipped as a buy, at Royal Bank of Canada, so long as management execute on its plan to ‘normalise' in the coming months – that means no more write-offs and an altogether steadier few months of trading.

Reckitt Benckiser has had a ‘buy' view reiterated by Royal Bank of Canada (TSX:RY) analysts, who hope management's assertion that things are about normalise proves accurate. “In the absence of further one-offs, and with a chief executive announcement expected during the first half of 2023, we believe that Reckitt's undervaluation will become increasingly apparent.

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) reported double digit growth in operating profit and earnings per share and was in confident mood as it entered 2023. Full year revenue rose 9.2% to £14.45bn in the year to December 31, operating profit jumped 16.8% to £3.44bn and EPS advanced 18.4% to 341.7p.

Full-year results from Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) come four months from its last update, in which time rival Unilever reported a squeeze on margins due to input cost inflation. The October update from the maker of everything from Durex condoms and Clearasil spot creams, to Air Wick fresheners and Nutramigen infant formula, revealed slower sales growth but continued confidence that it would be able to pass on all cost hikes to consumers for the rest of the year.